Pharmacy
Aspects of this proposed policy will affect nearly all hospitals paid under the Outpatient Prospective Payment System, CMS says.
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval.
The list of the first 10 drugs covered under Part D selected for initial price applicability year 2026 will be announced September 1.
Medicare will cover drugs with traditional FDA approval when a physician and clinical team participates in a registry.
Drug negotiation with manufacturers is government price fixing and is unconstitutional, groups say.
The science is there, but not the capital to get certain drugs to market. That means choices are being made, one says.
HIMSS23
When providers have conversations with patients and switch to lower-cost drugs, individuals are saving an average of $61 on prescriptions, says Dr. Andrew Mellin, CMIO at Surescripts.
Expansion eligibility for the full low-income subsidy-benefit arrives as many are losing Medicaid coverage in the redetermination process.
CMS intends to send the first invoices in 2025 to manufacturers for the rebates owed to Medicare in 2023 and 2024.
The move is an effort to expand and accelerate pharmacy care delivery for patients with chronic and complex care needs.